Newport Trust Co cut its stake in shares of Humana Inc (NYSE:HUM) by 2.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,696,091 shares of the insurance provider’s stock after selling 43,967 shares during the quarter. Humana makes up approximately 1.2% of Newport Trust Co’s holdings, making the stock its 11th biggest position. Newport Trust Co’s holdings in Humana were worth $433,640,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in HUM. Pensionfund DSM Netherlands boosted its stake in Humana by 11.0% in the 2nd quarter. Pensionfund DSM Netherlands now owns 10,100 shares of the insurance provider’s stock worth $2,680,000 after purchasing an additional 1,000 shares during the period. Pensionfund Sabic boosted its stake in Humana by 11.7% in the 2nd quarter. Pensionfund Sabic now owns 6,700 shares of the insurance provider’s stock worth $1,778,000 after purchasing an additional 700 shares during the period. Crossmark Global Holdings Inc. boosted its stake in Humana by 5.7% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 15,341 shares of the insurance provider’s stock worth $4,070,000 after purchasing an additional 823 shares during the period. Scout Investments Inc. boosted its stake in Humana by 440.3% in the 2nd quarter. Scout Investments Inc. now owns 79,217 shares of the insurance provider’s stock worth $21,016,000 after purchasing an additional 64,555 shares during the period. Finally, First National Bank of Omaha boosted its stake in Humana by 17.8% in the 2nd quarter. First National Bank of Omaha now owns 20,529 shares of the insurance provider’s stock worth $5,446,000 after purchasing an additional 3,099 shares during the period. Institutional investors own 92.93% of the company’s stock.

In other news, insider Brian P. Leclaire sold 7,239 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the sale, the insider now directly owns 12,994 shares of the company’s stock, valued at approximately $3,764,361.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.54% of the stock is owned by corporate insiders.

Several research firms have weighed in on HUM. Mizuho began coverage on Humana in a research note on Thursday, October 17th. They issued a “buy” rating and a $316.00 price target for the company. Citigroup upped their price target on Humana from $340.00 to $350.00 and gave the stock a “buy” rating in a research note on Thursday. Morgan Stanley dropped their price target on Humana from $342.00 to $337.00 and set an “overweight” rating for the company in a research note on Thursday, September 26th. Canaccord Genuity restated a “buy” rating on shares of Humana in a research note on Monday, October 21st. Finally, Cantor Fitzgerald upgraded Humana from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $300.00 to $345.00 in a research note on Monday, August 12th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and seventeen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $335.45.

Shares of HUM traded up $2.44 during mid-day trading on Friday, hitting $317.58. 1,421,500 shares of the stock were exchanged, compared to its average volume of 1,220,728. The company has a market cap of $39.82 billion, a PE ratio of 21.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.85. Humana Inc has a 52-week low of $225.65 and a 52-week high of $342.03. The firm has a 50-day moving average of $277.48 and a two-hundred day moving average of $270.93. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.75 and a current ratio of 1.75.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, November 6th. The insurance provider reported $5.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $4.58 by $0.45. The business had revenue of $16.24 billion for the quarter, compared to analysts’ expectations of $16.15 billion. Humana had a return on equity of 22.47% and a net margin of 4.13%. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the prior year, the firm earned $4.58 EPS. On average, sell-side analysts predict that Humana Inc will post 17.75 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.55 per share. The ex-dividend date of this dividend is Monday, December 30th. This represents a $2.20 annualized dividend and a dividend yield of 0.69%. Humana’s dividend payout ratio (DPR) is 15.12%.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Recommended Story: Consumer behavior in bull markets

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.